Tranexamic Acid (TXA) in Hip Arthroscopy

• Status: Withdrawn
• Trial end date: 2024-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The primary goal of this study will be to determine if perioperative IV Tranexamic Acid (TXA) administration will reduce intra-operative bleeding and subsequently improve visual clarity during surgery and reduce operative traction time in patients undergoing hip arthroscopy. Additionally, this study aims to determine whether IV TXA injections will reduce post-operative pain and affect hip-specific patient-reported outcomes in patients undergoing hip arthroscopy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Northwestern University
• Treatments: Tranexamic Acid

Criteria

Inclusion Criteria:

• Age 18 years or older

• Scheduled to undergo primary hip arthroscopy for any intra-articular procedure

• Able to complete and understand study materials in English

Exclusion Criteria:

• Age under 18 years

• Cannot complete and understand study materials in English

• Patients undergoing revision surgery

• Patients who have had previous surgery to the study joint

• Patients on drugs that interfere with coagulation or TXA clearance

• Patients with a known allergy to TXA

• Patients with any of the following comorbidities

• Bleeding and/or coagulative disorders

• Renal impairment

• Sickle cell disease

• Thrombotic diseases

• Comorbidities preventing surgery (including pregnancy)